Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient Preference for Weekly vs Daily DPP-4 Inhibitors in Type 2 Diabetes
jRCT1080223606Phase 4Completed
- Sponsor
- Takeda
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of trelagliptin and alogliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Takeda. Started Aug 2017; status: completed.
02
Drugs
trelagliptinalogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1080223606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223606.